Developer docs
API playgroundTry for free, no card

Search company profiles

Phastar

Full company profile

uuid0007iy5

Namestring
Phastar
Websiteurl
phastar.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Phastar is a global specialist biometrics and data science contract research organization (CRO) founded in 2007 and headquartered in London. The company serves pharmaceutical, biotechnology, and health agency clients by providing statistical consulting, clinical trial reporting, data science, and data management services for regulated clinical development programs. Phastar targets sponsors seeking Functional Service Provider (FSP) engagement models with deep biometrics domain expertise rather than full-service bundled offerings.

The company's core service portfolio comprises four integrated offerings: Biometrics Services (statistical analysis, clinical trial design, and statistical programming), Data Science Services (advanced analytics for clinical development), Clinical Data Management (handling, validation, and regulatory compliance), and Data Visualization Solutions (acquired via Danish firm S-Cubed ApS in January 2023, adding specialized visual analytics for regulated environments). A Strategic Consulting practice, launched in June 2025 under Billy Amzal, extends the offering into advisory services for adaptive trial designs, Bayesian statistics, real-world evidence integration, and innovative methodologies including patient simulators and synthetic patients.

Phastar operates a project-based and FSP professional services revenue model with quote-based, non-publicly-disclosed pricing typical of the CRO industry. The company has grown to approximately 550 employees globally following the S-Cubed acquisition, and is privately held under the sponsorship of Charterhouse Capital Partners (invested January 2021). Distribution is direct enterprise sales targeting pharma/biotech sponsors and health agencies, with senior leadership engagement as the primary commercial motion. The Clinical Trial Data Visualization sub-market in which Phastar competes is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at approximately 15% CAGR, providing a supportive demand backdrop.

Short descriptiontext

Phastar is a London-based specialist biometrics and data science CRO serving pharmaceutical, biotech, and health agency clients with statistical consulting, clinical data management, data visualization, and strategic consulting services for regulated clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biometrics CRO services, clinical data management, statistical consulting, clinical trial reporting, data science services
Industry3 codes
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAK
Real-World Evidence (RWE), HEOR & Epidemiology CROs
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Organization (CRO) Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization Services
TypeProfessional Services
Description

Phastar provides specialized biometrics and data science services as a CRO, likely operating on project-based or functional service provider (FSP) models typical in the clinical research industry

contractpharma.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Phastar is a specialist contract research organization (CRO) providing biometrics and data science services to pharmaceutical and biotech sponsors. Its core offerings include biometrics services (statistical analysis, trial design, statistical programming), data science services, and clinical data management, supplemented by data visualization capabilities acquired through S-Cubed ApS and strategic consulting on adaptive trial designs and real-world evidence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Workforce expanded to approximately 550 people globally
+1 more record
Product overview1 text field

Phastar is a global specialist biometrics and data science contract research organization (CRO) offering a unified platform of services for pharmaceutical and biotech clients. The core offering consists of Biometrics Services, Data Science Services, and Clinical Data Management, which work together to support the full clinical development lifecycle. The portfolio was expanded through the January 2023 acquisition of S-Cubed ApS, adding Data Visualization Solutions to enhance data presentation capabilities in regulated environments. Strategic Consulting services, led by Head of Strategic Consulting Billy Amzal, provide advisory capabilities on adaptive trial designs and real-world evidence integration. The combined expertise aims to improve data analysis and visualization across clinical trial programs.

Product and service5 records
1Biometrics Services
CategoryBiometrics CRO Services
2Data Science Services
CategoryData Science CRO Services
3Clinical Data Management
CategoryClinical Data Management
4Data Visualization Solutions
CategoryClinical Data Visualization
5Strategic Consulting
CategoryStrategic Consulting Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-24
Description

Billy Amzal, previously CEO of Quinten Health, joined Phastar as Head of Strategic Consulting. Phastar will continue collaborating with Quinten Health on strategic initiatives, leveraging their existing relationship in health analytics and consulting.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Acquired Danish data visualization company S-Cubed ApS in January 2023 to strengthen Phastar's presence in the Nordic region and enhance its data visualization capabilities for clinical data management in regulated environments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Veramed is a UK-based specialist biometrics CRO offering biostatistics, statistical programming, and data management. Its boutique scale, biometrics focus, and pharma/biotech sponsor base closely mirror Phastar's positioning.

TypeBroad incumbent
Description

Parexel is a major full-service CRO with deep biometrics and biostatistics capabilities following the 2021 PAI integration. It competes with Phastar for FSP and full-service engagements, particularly among biotech sponsors.

TypeBroad incumbent
Description

Clario (formed from ERT and Bioclinica) provides clinical trial technology and services including eCOA, imaging, and data management. Its data visualization and clinical data tooling overlap with Phastar's post-S-Cubed capabilities.

TypeBroad incumbent
Description

ICON is a top-three global CRO with extensive biometrics, data management, and FSP capabilities. Its broad portfolio overlaps with Phastar across pharma/biotech biometrics services and represents a competitive threat for mid-tier sponsor accounts.

TypeBroad incumbent
Description

Medidata offers the Rave clinical data platform and end-to-end clinical trial technology used by sponsors and CROs. Its Rave data management and analytics capabilities compete with and complement Phastar's biometrics services.

TypeBroad incumbent
Description

IQVIA is the largest global CRO with full-service clinical operations and a large biometrics/Real World Solutions practice. It competes with Phastar for enterprise FSP contracts and serves as the dominant reference point for CRO multiples.

TypeDirect peer
Description

Statistics Collaborative is a boutique biometrics CRO specializing in biostatistics, statistical programming, and clinical study reporting. Its specialist focus and pharma/biotech sponsor mix make it a relevant small-scale peer to Phastar.

TypeRegional player
Description

Worldwide Clinical Trials is a mid-sized CRO with strong biostatistics and clinical pharmacology capabilities primarily serving biotech sponsors in North America and Europe. It is comparable to Phastar in scale and sponsor focus, though with less UK/European concentration.

TypeDirect peer
Description

Cytel is the leading specialist biometrics and statistical CRO, providing biostatistics, statistical programming, and clinical data management services to pharma and biotech sponsors. It is the closest direct competitor to Phastar's biometrics FSP offering.

10Rho
TypeDirect peer
Description

Rho is a mid-sized specialty CRO with strong biostatistics and clinical data management capabilities serving biotech and pharma sponsors. It competes with Phastar for FSP biometrics engagements in the mid-market sponsor segment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phastar

Clinical Research Organization (CRO) Servicesphastar.com

Phastar is a London-based specialist biometrics and data science CRO serving pharmaceutical, biotech, and health agency clients with statistical consulting, clinical data management, data visualization, and strategic consulting services for regulated clinical trials.

What Phastar does

Phastar is a global specialist biometrics and data science contract research organization (CRO) founded in 2007 and headquartered in London. The company serves pharmaceutical, biotechnology, and health agency clients by providing statistical consulting, clinical trial reporting, data science, and data management services for regulated clinical development programs. Phastar targets sponsors seeking Functional Service Provider (FSP) engagement models with deep biometrics domain expertise rather than full-service bundled offerings.

The company's core service portfolio comprises four integrated offerings: Biometrics Services (statistical analysis, clinical trial design, and statistical programming), Data Science Services (advanced analytics for clinical development), Clinical Data Management (handling, validation, and regulatory compliance), and Data Visualization Solutions (acquired via Danish firm S-Cubed ApS in January 2023, adding specialized visual analytics for regulated environments). A Strategic Consulting practice, launched in June 2025 under Billy Amzal, extends the offering into advisory services for adaptive trial designs, Bayesian statistics, real-world evidence integration, and innovative methodologies including patient simulators and synthetic patients.

Phastar operates a project-based and FSP professional services revenue model with quote-based, non-publicly-disclosed pricing typical of the CRO industry. The company has grown to approximately 550 employees globally following the S-Cubed acquisition, and is privately held under the sponsorship of Charterhouse Capital Partners (invested January 2021). Distribution is direct enterprise sales targeting pharma/biotech sponsors and health agencies, with senior leadership engagement as the primary commercial motion. The Clinical Trial Data Visualization sub-market in which Phastar competes is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at approximately 15% CAGR, providing a supportive demand backdrop.

Phastar firmographics

Firmographics
Name
Phastar
Website
https://phastar.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
251–500 employees
Short description
Phastar is a London-based specialist biometrics and data science CRO serving pharmaceutical, biotech, and health agency clients with statistical consulting, clinical data management, data visualization, and strategic consulting services for regulated clinical trials.
Ownership category
akta.pro rank

Phastar industry classification

Industry
Product category
Clinical Research Organization (CRO) Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAK
Real-World Evidence (RWE), HEOR & Epidemiology CROs

Keywords

  • Biometrics CRO services
  • Clinical data management
  • Statistical consulting
  • Clinical trial reporting
  • Data science services

Where Phastar is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Phastar business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Organization Services: Phastar provides specialized biometrics and data science services as a CRO, likely operating on project-based or functional service provider (FSP) models typical in the clinical research industry

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Phastar product offering

Product offering

Core offering

Phastar is a specialist contract research organization (CRO) providing biometrics and data science services to pharmaceutical and biotech sponsors. Its core offerings include biometrics services (statistical analysis, trial design, statistical programming), data science services, and clinical data management, supplemented by data visualization capabilities acquired through S-Cubed ApS and strategic consulting on adaptive trial designs and real-world evidence.

Product overview

Phastar is a global specialist biometrics and data science contract research organization (CRO) offering a unified platform of services for pharmaceutical and biotech clients. The core offering consists of Biometrics Services, Data Science Services, and Clinical Data Management, which work together to support the full clinical development lifecycle. The portfolio was expanded through the January 2023 acquisition of S-Cubed ApS, adding Data Visualization Solutions to enhance data presentation capabilities in regulated environments. Strategic Consulting services, led by Head of Strategic Consulting Billy Amzal, provide advisory capabilities on adaptive trial designs and real-world evidence integration. The combined expertise aims to improve data analysis and visualization across clinical trial programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biometrics Services
  • Data Science Services
  • Clinical Data Management
  • Data Visualization Solutions
  • Strategic Consulting

Quantifiable outcome

  • Workforce expanded to approximately 550 people globally
  • +1 more outcomes

Companies that use Phastar

Customer profile

Segments2 records

Ideal customer profiles2 records

Phastar technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Phastar partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Quinten HealthminorStrategic or Co-development Partner · 24 June 2025Billy Amzal, previously CEO of Quinten Health, joined Phastar as Head of Strategic Consulting. Phastar will continue collaborating with Quinten Health on strategic initiatives, leveraging their existing relationship in health analytics and consulting.
  • S-Cubed ApScoreStrategic or Co-development Partner · 1 January 2023Acquired Danish data visualization company S-Cubed ApS in January 2023 to strengthen Phastar's presence in the Nordic region and enhance its data visualization capabilities for clinical data management in regulated environments.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Phastar competitors and assessment

Company assessment

Direct peers

  • Veramed: Veramed is a UK-based specialist biometrics CRO offering biostatistics, statistical programming, and data management. Its boutique scale, biometrics focus, and pharma/biotech sponsor base closely mirror Phastar's positioning.
  • Statistics Collaborative: Statistics Collaborative is a boutique biometrics CRO specializing in biostatistics, statistical programming, and clinical study reporting. Its specialist focus and pharma/biotech sponsor mix make it a relevant small-scale peer to Phastar.
  • Cytel: Cytel is the leading specialist biometrics and statistical CRO, providing biostatistics, statistical programming, and clinical data management services to pharma and biotech sponsors. It is the closest direct competitor to Phastar's biometrics FSP offering.
  • Rho: Rho is a mid-sized specialty CRO with strong biostatistics and clinical data management capabilities serving biotech and pharma sponsors. It competes with Phastar for FSP biometrics engagements in the mid-market sponsor segment.

Broad incumbents

  • Parexel: Parexel is a major full-service CRO with deep biometrics and biostatistics capabilities following the 2021 PAI integration. It competes with Phastar for FSP and full-service engagements, particularly among biotech sponsors.
  • Clario: Clario (formed from ERT and Bioclinica) provides clinical trial technology and services including eCOA, imaging, and data management. Its data visualization and clinical data tooling overlap with Phastar's post-S-Cubed capabilities.
  • ICON plc: ICON is a top-three global CRO with extensive biometrics, data management, and FSP capabilities. Its broad portfolio overlaps with Phastar across pharma/biotech biometrics services and represents a competitive threat for mid-tier sponsor accounts.
  • Medidata (Dassault Systèmes): Medidata offers the Rave clinical data platform and end-to-end clinical trial technology used by sponsors and CROs. Its Rave data management and analytics capabilities compete with and complement Phastar's biometrics services.
  • IQVIA: IQVIA is the largest global CRO with full-service clinical operations and a large biometrics/Real World Solutions practice. It competes with Phastar for enterprise FSP contracts and serves as the dominant reference point for CRO multiples.

Regional players

  • Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized CRO with strong biostatistics and clinical pharmacology capabilities primarily serving biotech sponsors in North America and Europe. It is comparable to Phastar in scale and sponsor focus, though with less UK/European concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Phastar social profiles

Digital presence

Phastar financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phastar leadership team

Management profile

Number of profiles

Profiles1 record

Phastar subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Phastar funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phastar M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phastar

What does Phastar do?

Phastar is a specialist contract research organization (CRO) providing biometrics and data science services to pharmaceutical and biotech sponsors. Its core offerings include biometrics services (statistical analysis, trial design, statistical programming), data science services, and clinical data management, supplemented by data visualization capabilities acquired through S-Cubed ApS and strategic consulting on adaptive trial designs and real-world evidence.

Is Phastar a public or private company?

Phastar is a private company. It is classified as private equity controlled and is currently operating.

When was Phastar founded?

Phastar was founded in 2007. It employs 251 to 500 people.

Where is Phastar based?

Phastar is headquartered in London, United Kingdom, in the Europe region.

How does Phastar make money?

One revenue line is on record: contract Research Organization Services.

Who are Phastar's main competitors?

Direct peers on record are Veramed, Statistics Collaborative, Cytel and Rho. Broad incumbents are Parexel, Clario, ICON plc, Medidata (Dassault Systèmes) and IQVIA. Worldwide Clinical Trials is listed as a regional player.

Does Phastar have an API?

No public API is recorded for Phastar.

What industry is Phastar in?

Phastar's product category is Clinical Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooClinical Trial Data Visualization Research Report 2026: $1.82 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FResearchAndMarkets.com has released its Clinical Trial Data Visualization Market Report 2026, projecting the market to grow from $0.89 billion in 2025 to $1.82 billion by 2030, driven by a compound annual growth rate of approximately 15%. The report highlights key growth drivers including increasing clinical trial data complexity, expansion of decentralized trials, and rising adoption of AI-powered and cloud-based analytics solutions. Notable industry developments include Medidata Solutions' June 2024 launch of its AI-enabled Clinical Data Studio platform and Phastar's acquisition of S-cubed ApS in January 2023 to strengthen its data visualization capabilities.PhastarClinical Data ManagementPhastar offers comprehensive clinical data management solutions for pharmaceutical clients, covering the entire clinical trial spectrum from Phase I to Phase IV. The company utilizes proprietary tools and integrates with systems like Medidata and Medrio to ensure high-quality, compliant data handling through automated flagging and expert oversight. A client testimonial highlights Phastar's ability to deliver rapid responses to regulatory agencies under tight deadlines.PharmiWeb.comPhastar appoints Industry Veteran Billy Amzal as Head of Strategic ConsultingPhastar, a global specialist biometrics and data science contract research organization, announced the appointment of Billy Amzal as Head of Strategic Consulting. Amzal brings over 25 years of experience across biotech, pharmaceuticals, health agencies, and consulting, with expertise spanning adaptive trial designs, Bayesian statistics, and real-world evidence. He previously served as Senior Vice President at Certara and CEO of Quinten Health, with whom Phastar will continue collaborating on strategic initiatives.outsourcing-pharma.comDiscover how Phastar is making a vast contribution the life sciences community at DIA 2024Phastar, a CRO, will present its sustainability and community initiatives at DIA 2024, including a net-zero-by-2035 target and a partnership with Beaconcure for AI-enabled clinical data validation. The company also launched a Clinical Intelligence Portal with AI-powered review and predictive modeling.ContractpharmaBeaconcure Partners with Phastar to Enhance Clinical Trial Review ProcessesBeaconcure and Phastar partnered to integrate Beaconcure's Verify platform into Phastar's clinical trial review processes. The collaboration aims to reduce human error, improve data integrity, and shorten review cycles. Both companies plan to explore new industry standards to increase speed and compliance in clinical trials.ContractpharmaBeaconcure Partners with Phastar to Enhance Clinical Trial Review ProcessesBeaconcure Inc. has partnered with Phastar Inc., a global biometrics contract research organization, to integrate Beaconcure's Verify platform into Phastar's clinical trial review processes. This collaboration aims to reduce human error, improve data integrity, and accelerate the delivery of drugs by streamlining validation and approval cycles.PhastarPhastar Enhances Data Visualisation and Analytics Solution Through Acquisition of S-Cubed ApSPhastar announced the acquisition of S-Cubed ApS, a specialist biometrics and data visualisation company based in Denmark. This transaction expands Phastar's workforce to approximately 550 employees globally and strengthens its operational presence in the Nordic region while enhancing its data analytics capabilities.PR NewswirePhastar enhances Data Visualization and Analytics solution through acquisition of S-Cubed ApS, adds capability in DenmarkPhastar has acquired S-Cubed ApS, a company specializing in biometrics and data visualization, enhancing Phastar's capabilities in the Nordic region. This acquisition increases the PHASTAR group to approximately 550 employees and is expected to improve service delivery for customers in the area. The collaboration aims to address the growing data challenges in the life sciences sector, incorporating advanced visualization and analytical tools.MedidataNext-generation Clinical Data Management | A Case Study CollectionMedidata published a case study collection describing how sponsors and CROs are adopting its clinical data management solutions to handle growing trial data complexity. Featured examples include Southampton Clinical Trials Unit's move to 100% electronic data capture, PHASTAR's migration of over 10,000 data points across 70+ electronic case report forms, and Onconova's use of Rave Coder, Targeted SDV, EDC and RTSM.ContractpharmaMedrio and Phastar Partner to Leverage Metadata for Advanced Data VisualizationMedrio and Phastar partnered to use metadata from electronic patient-reported outcomes for advanced data visualization, aiming to monitor compliance and patient burden. Phastar ran a pilot with 33 volunteers completing EQ-5D, using Medrio's ePRO and Export API to feed data into Phizual. The companies plan to continue collaborating to improve data quality and accuracy.